OREX - Orexigen Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Orexigen Therapeutics, Inc.

3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
United States

IndustryDrug Manufacturers - Other
Full Time Employees132

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. NarachiPres, Chief Exec. Officer & Director1.15MN/A1959
Dr. Thomas R. Cannell D.V.M.Exec. VP, COO & Pres of Global Commercial Products691.11kN/A1962
Mr. Thomas P. LynchExec. VP, Gen. Counsel, Chief Admin. Officer & Sec.552.37kN/A1967
Ms. Monica ForbesVP & Acting CFON/AN/A1976
Mr. Stephen A. MogliaChief Accounting Officer, VP and ControllerN/AN/A1965
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

Orexigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.